Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

This study tests whether donor T cell therapy — infusing immune cells (T cells) taken from the original stem cell transplant donor — can help immunocompromised patients fight adenovirus infections. Adenovirus can cause severe, sometimes fatal infections in patients whose immune systems are weakened after a stem cell transplant. Standard antiviral medications often fail or cause significant toxicity in these patients. Participants receive specially selected T cells from their original donor that are designed to target adenovirus. This is a treatment study for a serious, hard-to-treat infection. You may be eligible if: - You are immunocompromised (any age, 1 year or older) - You have asymptomatic adenovirus viremia (two positive qPCR tests one week apart, or one test ≥1000 copies) OR probable/definitive adenoviral disease - Your original stem cell donor is available - Negative pregnancy test if you are a woman of childbearing potential You may NOT be eligible if: - You are receiving prednisone >0.1 mg/kg/day or have received ATG within 14 days or DLI/Campath within 28 days - You have other uncontrolled infections (bacterial infections progressing despite therapy, or fungal infections progressing despite antifungals) - You have active acute graft-versus-host disease (GVHD) Grade 2 or higher Talk to your doctor to see if this trial is right for you.